[
    {
        "id": "osp-12717",
        "type": "article-journal",
        "title": "Experience of intravitreal injections in a tertiary Hospital in Oman",
        "author": [
            {
                "family": "Al-Hinai",
                "given": "Ahmed S"
            }
        ],
        "URL": "https://omanscience.com/en/articles/experience-of-intravitreal-injections-in-a-tertiary-hospital-in-oman",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2015
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "8",
        "issue": "3",
        "page": "166-170",
        "DOI": "10.4103/0974-620x.169896",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Aim: To find out statistical data regarding intravitreal injections in an outpatient department setup at a tertiary center in Oman.\n\nDesign: Retrospective chart review.\n\nMethods: Data collection of patients who underwent intravitreal injections from November 2009 to May 2013 at Sultan Qaboos University Hospital.\n\nResults: Throughout a period of 42 months, a total of 711 intravitreal injections were performed. That included 214 patients (275 eyes). Around one-third of the eyes received two injections or more. The injected agents were bevacizumab (59.8%), ranibizumab (32.3%), triamcinolone (7.5%), and very few patients with endophthalmitis received intravitreal antibiotics and antifungal agents. The three most common indications for the injection therapy were diabetic macular edema (50.9%), choroidal neovascularization (24.3%), and retinal vein occlusive diseases (11.5%). Serious adverse events were rare, and they occurred as ocular (0.9% per patient) and systemic (3.3% per patient). There were 42 eyes received intravitreal triamcinolone, and 24% of them developed intraocular hypertension that required only medical treatment.\n\nConclusion: Different intravitreal agents are currently used to treat many ocular diseases. Currently, therapy with intravitreal agents is very popular, and it carries a promising outcome with more efficiency and safety."
    }
]